Alnylam Pharmaceuticals
ALNY
#581
Rank
ยฃ27.34 B
Marketcap
ยฃ212.00
Share price
2.75%
Change (1 day)
60.01%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -ยฃ3.30

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -ยฃ3.18. In 2022 the company made an earnings per share (EPS) of -ยฃ7.19 a decrease over its 2021 EPS that were of -ยฃ5.57.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-ยฃ3.30-54.06%
2022-ยฃ7.1929.03%
2021-ยฃ5.57-3.36%
2020-ยฃ5.77-8.48%
2019-ยฃ6.307.67%
2018-ยฃ5.8539.74%
2017-ยฃ4.1912.94%
2016-ยฃ3.7138.84%
2015-ยฃ2.67-32.88%
2014-ยฃ3.98259.44%
2013-ยฃ1.11-31.25%
2012-ยฃ1.6152.94%
2011-ยฃ1.0530.77%
2010-ยฃ0.80-8.77%
2009-ยฃ0.8878.13%
2008-ยฃ0.50-70.78%
2007-ยฃ1.7099.09%
2006-ยฃ0.85-43.88%
2005-ยฃ1.52-82.33%
2004-ยฃ8.59-59.23%
2003-ยฃ21.06

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-ยฃ1.32-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ28.92-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ6.06 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.21-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ1.31-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ2.89-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ2.46-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-ยฃ1.55-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel